Chongqing Qingyutang Pharmaceutical Co. Ltd.

Primary Study Objective: To conduct a bioequivalence study using oxazepam tablets (15mg) manufactured by Qingyutang Pharmaceutical Co., Ltd. (a subsidiary of Fu'an Pharmaceutical Group) as the test formulation (T), and oxazepam tablets (15mg, trade name: Sobril®) manufactured by Pfizer AS as the reference formulation (R), in accordance with relevant bioequivalence study regulations. Secondary Study Objective: To observe the safety of the test formulation oxazepam tablets and the reference formulation oxazepam tablets in healthy subjects.

Primary Study Objective: To assess the bioequivalence of a single oral dose of the test formulation (5 mg, manufactured by Qingyutang Pharmaceutical Co., Ltd., Fu'an Pharmaceutical Group) and the reference formulation (trade name: DAYVIGO®, 5 mg, licensed by Aezai Co., Ltd.) of Leborexen tablets in healthy subjects after a meal. Secondary Study Objective: To observe the safety of the test and reference formulations of Leborexen tablets in healthy subjects.

Primary Objective: This study used cefoperazone hydrochloride granules (50 mg, calculated as C17H19N5O6S2) from Qingyutang Pharmaceutical Co., Ltd., a subsidiary of Fu'an Pharmaceutical Group, as the test formulation. Following the relevant regulations for bioequivalence studies, cefoperazone hydrochloride granules (50 mg, calculated as C17H19N5O6S2) from the original manufacturer, SHIONOGI & Co., LTD., was used as the reference formulation to evaluate the bioequivalence of the test and reference formulations under fasting/postprandial administration conditions. Secondary Objective: To observe the safety of the test and reference formulations of cefoperazone hydrochloride granules in healthy subjects.